Table 1. Study characteristics.
Author (Year) Country Study Design N of acne patients Age (years) Oral isotretinoin dosage Treatment duration (months) Control Parameters assessed
Laker (1987)24 U.K. Cohort 13 (M:F = 10:3) 13-32* 1.0 mg/kg/day 4 no glucose, insulin
Koistinen (2001)25 Finland Cohort 11 (M:F=11:0) 24 (2)^ ∼0.5 mg/kg/day 4–6 no glucose,HbA1c%, insulin
Stoll (2004)26 Switzerland Cohort 15 (M:F=15:0) 28.3 (1.7)^ 1.0 mg/kg/day 5 days1 no glucose, insulin
Koistinen (2006)27 Finland Cohort 11 (M:F=11:0) 24 (2)^ ∼0.5 mg/kg/day 5 (6-10)* no adiponectin
Heliövaara (2007)28 Finland Cohort 23 (M:F=12:11) 24.9 (0.9)^ N/A 3 no adiponectin, glucose, insulin
Ertugrul (2010)7 Turkey Cohort 48 (M:F=13:35) 22 (18-38)** 0.5–0.75 mg ⁄kg/day, adjusted to 0.88 mg ⁄kg ⁄day 1 month after ≥4 no glucose, insulin, HOMA-IR
Cetinözman (2013)29 Turkey Case-control 26 (M:F=0:26) 24.7 (3.9)^ 20mg/day increased to max.50mg/day 7.5 (6-10)* yes glucose/insulin, HOMA-IR
Karadag (2015)30 Turkey Case-control 33 (M:F=15:18) 19.8 (4.1)^ N/A 3 yes adiponectin, glucose, insulin
Cemil (2016)31 Turkey Cohort 32 (M:F=20:12) 18.9 (2.57)^ 0.5-0.6mg/kg/day adjusted to 0.6-0.75 mg/kg/day after 1 month 3 no adiponectin
Saklamaz (2016)19 Turkey Cohort 21 (M:F=6:15) 23.0 (4.1)^ 0.5-0.8 mg/kg/day 4 no glucose, insulin, HOMA-IR
Aydin (2017)20 Turkey Case-control 18 (M:F=0:18) 23.4 (3.4)^ 20mg/day increased to max.50mg/day 6 yes adiponectin, glucose, insulin, HOMA-IR
Soyuduru (2019)8 Turkey Case-control 29 (M:F=15:14) 20.5 (1.9)^ 0.5 mg/kg/day 5 yes adiponectin, HOMA-IR
Acmaz (2019)21 Turkey Cohort 40 (M:F=0:40) 18-40* 20 mg/day increased to max. 40mg/day 6 no insulin
Koçyiğit (2020)22 Turkey Case-control 30 (M:F=0:30) 23.2 (3.7)^ 120-150 mg/kg/day 3 yes glucose, insulin, HOMA-IR
Aktar (2021)23 Turkey Case-control 30 (M:F=0:30) 22.1 (3.4)^ 0.5mg/kg/day 3 yes glucose, insulin
Abbreviations: F, females; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; M, males; N/A, not available. Abbreviations: F, females; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; M, males; N/A, not available. Abbreviations: F, females; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; M, males; N/A, not available. Abbreviations: F, females; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; M, males; N/A, not available. Abbreviations: F, females; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; M, males; N/A, not available. Abbreviations: F, females; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; M, males; N/A, not available. Abbreviations: F, females; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; M, males; N/A, not available. Abbreviations: F, females; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; M, males; N/A, not available. Abbreviations: F, females; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; M, males; N/A, not available.
*Range ^Mean (SD) **Median (IQR) 1Previous treatment with isotretinoin on average 5 years earlier (3-10) *Range ^Mean (SD) **Median (IQR) 1Previous treatment with isotretinoin on average 5 years earlier (3-10) *Range ^Mean (SD) **Median (IQR) 1Previous treatment with isotretinoin on average 5 years earlier (3-10) *Range ^Mean (SD) **Median (IQR) 1Previous treatment with isotretinoin on average 5 years earlier (3-10) *Range ^Mean (SD) **Median (IQR) 1Previous treatment with isotretinoin on average 5 years earlier (3-10) *Range ^Mean (SD) **Median (IQR) 1Previous treatment with isotretinoin on average 5 years earlier (3-10) *Range ^Mean (SD) **Median (IQR) 1Previous treatment with isotretinoin on average 5 years earlier (3-10) *Range ^Mean (SD) **Median (IQR) 1Previous treatment with isotretinoin on average 5 years earlier (3-10) *Range ^Mean (SD) **Median (IQR) 1Previous treatment with isotretinoin on average 5 years earlier (3-10)